- {{heading}}
- Ab03969-23.0 Anti-PSMA [8C12]
- Human
- Rabbit IgG
- Purified
- Ships in 5-6 weeks
Recombinant monoclonal antibody to PSMA. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 8C12.
UniProt Accession Number of Target Protein: Q04609
Alternative Name(s) of Target: PSM; FOLH1; FOLH; FGCP; GCPII; mGCP; NAALAD1; GIG27; Prostate specific membrane antigen; Glutamate carboxypeptidase 2; Cell growth-inhibiting gene 27 protein; Folate hydrolase 1; Folylpoly-gamma-glutamate carboxypeptidase; Glutamate carboxypeptidase II; Membrane glutamate carboxypeptidase; N-acetylated-alpha-linked acidic dipeptidase I; NAALADase I; Prostate-specific membrane antigen; Pteroylpoly-gamma-glutamate carboxypeptidase
Immunogen: The original antibody was generated by immunizing transgenic mice with PSMA.
Specificity: The antibody is specific for PSMA. The antibody recognises a conformational epitope.
Application Notes: The specificity of the antibody for PSMA was determined by ELISA analysis. The ability of the original format of the antibody and the bispecific 14A8 x 8C12 antibody to bind to PSMA-expressing LNCaP cells and CD89-expressing U937 cells was evaluated by solid phase ELISA. The antibody demonstrated high specificity for LNCaP cell membranes over a range of antigen concentrations, while the bispecific molecule binds both LNCaP and U937 cells in a dose-dependent fashion. The original format of the antibody immunoprecipitated PSMA from LNCaP Cells. This antibody was used for detection of PSMA expressed on LNCaP cells by flow cytometry. The original format and the bispecific 14A8 x 8C12 antibodies were tested for cell- mediated ADCC killing of labeled PSMA-expressing tumor cells. The results showed that both versions mediated dose dependent lysis by monocytes of LNCaP tumor cells. The original format and the bispecific 14A8 x 8C12 were tested for their ability to mediate phagocytosis of labeled PSMA-expressing tumor cells (LNCaP cells). Results showed that both were able to mediate phagocytosis of LNCaP cells in a dose dependent fashion (WO2003064606A3).
Antibody first published in: PMID: